Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Beam Therapeutics's Enterprise Value is $967.9 Mil.
Beam Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-176.5 Mil. Therefore, Beam Therapeutics's EV-to-EBIT ratio for today is -5.48.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Beam Therapeutics's Enterprise Value is $967.9 Mil.
Beam Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-156.5 Mil. Therefore, Beam Therapeutics's EV-to-EBITDA ratio for today is -6.19.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Beam Therapeutics's Enterprise Value is $967.9 Mil.
Beam Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $377.7 Mil. Therefore, Beam Therapeutics's EV-to-Revenue ratio for today is 2.56.
Beam Therapeutics Enterprise Value Historical Data
The historical data trend for Beam Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Beam Therapeutics Annual Data
Trend
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Enterprise Value
-
4,474.79
4,626.65
1,888.53
1,204.85
Beam Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Enterprise Value
1,888.53
1,396.20
1,591.38
1,066.27
1,204.85
Competitive Comparison
For the Biotechnology subindustry, Beam Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beam Therapeutics Enterprise Value Distribution
For the Biotechnology industry and Healthcare sector, Beam Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Beam Therapeutics's Enterprise Value falls into.
Beam Therapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Beam Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics (NAS:BEAM) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Beam Therapeutics's current Enterprise Value is $967.9 Mil.
Beam Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-176.5 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Beam Therapeutics's current Enterprise Value is $967.9 Mil.
Beam Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-156.5 Mil.
Beam Therapeutics's current Enterprise Value is $967.9 Mil.
Beam Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $377.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beam Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of Beam Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Beam Therapeutics (Beam Therapeutics) Business Description
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BEAM has been successfully added to your 